Loading ETF profile…
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| LLY | Eli Lilly and Company | 7.54% | $2.60M |
| ABBV | AbbVie Inc. | 7.25% | $2.50M |
| MRK | Merck & Co., Inc. | 6.92% | $2.39M |
| JNJ | Johnson & Johnson | 6.90% | $2.38M |
| BMY | Bristol-Myers Squibb Company | 6.38% | $2.20M |
| VTRS | Viatris Inc. | 3.78% | $1.30M |
| BIIB | Biogen Inc. | 3.68% | $1.27M |
| CAH | Cardinal Health, Inc. | 3.58% | $1.23M |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.38% | $1.17M |
| PFE | Pfizer Inc. | 3.20% | $1.11M |
| AMGN | Amgen Inc. | 3.20% | $1.11M |
| GILD | Gilead Sciences, Inc. | 3.01% | $1.04M |
| UTHR | United Therapeutics Corporation | 2.88% | $992.86K |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.83% | $977.72K |
| JAZZ | Jazz Pharmaceuticals Plc | 2.50% | $862.52K |
| INCY | Incyte Corporation | 2.32% | $799.60K |
| ZTS | Zoetis Inc. | 2.10% | $724.68K |
| ILMN | Illumina, Inc. | 1.96% | $675.06K |
| EXEL | Exelixis, Inc. | 1.71% | $590.67K |
| PTCT | PTC Therapeutics, Inc. | 1.45% | $500.91K |
| NBIX | Neurocrine Biosciences, Inc. | 1.38% | $475.28K |
| MEDP | Medpace Holdings, Inc. | 1.33% | $458.33K |
| ALKS | Alkermes Plc | 1.31% | $450.85K |
| CRL | Charles River Laboratories International, Inc. | 1.29% | $444.11K |
| BMRN | BioMarin Pharmaceutical Inc. | 1.16% | $399.51K |